A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
Clinical trial NCT06930651 · RECRUITING
Trial details
- NCT number
- NCT06930651
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-03
- Primary completion
- 2028-05-01
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.